Promising combo tackles relapsed lymphoma

NCT ID NCT02433795

Completed Disease control Sponsor: Seoul National University Hospital Source: ClinicalTrials.gov ↗

First seen Apr 29, 2026 · Last updated May 02, 2026 · Updated 2 times

Summary

This study tested a combination of two drugs, bendamustine and rituximab, in 27 adults whose marginal zone B-cell lymphoma had come back or worsened after prior treatment. The goal was to see how many patients' tumors shrank or disappeared. The approach uses established chemotherapy and immunotherapy to control the disease, not cure it.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Chonbuk National University Hospital

Jeonju, Jeollabuk-do, 54907, South Korea
Chungnam National University

Daejeon, South Korea
Gachon University Gil Medical Center

Incheon, South Korea
Gyeongsang National University Hospital

Jinju, South Korea
Hallym University Medical Center

Anyang-si, South Korea
Inje Universit

Seoul, South Korea
Korea Cancer Center Hospital

Seoul, South Korea
Seoul National University Boramae Hospital

Seoul, South Korea
Seoul National University Bundang Hospital

Seongnam, South Korea
Seoul National University Hospital

Seoul, South Korea
The Catholic University of Korea

Seoul, South Korea

Conditions

Explore the condition pages connected to this study.

MARGINAL ZONE B-CELL LYMPHOMA MARGINAL ZONE B-CELL LYMPHOMA